Oxcarbazepine-responsive paroxysmal kinesigenic dyskinesia in wilson disease

Clinical Neuropharmacology

Volumn 34, Issue 6, 2011, Pages 262-264

  Micheli, Federico ^a   Tschopp, Lorena ^b   Cersosimo, Maria Graciela ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

D penicillamine; dyskinesia; kinesigenic; paroxysmal; Wilson

Indexed keywords

GADOLINIUM; OXCARBAZEPINE; PENICILLAMINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DYSKINESIA; ELECTROENCEPHALOGRAPHY; HUMAN; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL KINESIGENIC DYSKINESIA; PRIORITY JOURNAL; REMISSION; SLIT LAMP; TREATMENT RESPONSE; WILSON DISEASE;

CARBAMAZEPINE; DYSTONIA; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; MOVEMENT DISORDERS; PENICILLAMINE; YOUNG ADULT;

EID: 82055165591     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182348964     Document Type: Article

References (32)

1. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-337. (Pubitemid 23351302)
2. Petrukhin K, Lutsenko S, Chernov I, et al. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994;3:1647-1656. (Pubitemid 24295463)
3. Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr 1987;146:261-265. (Pubitemid 17066922)
4. El-Youssef M. Wilson disease. Mayo Clin Proc 2003;78:1126-1136. (Pubitemid 37055657)
5. Van Rootselaar AF. The paroxysmal dyskinesias. Pract Neurol 2009;9:102-109.
6. Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003;10:68-79. (Pubitemid 36618341)
7. Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004;63:2280-2287. (Pubitemid 40024337)
8. Fragoso YD, Araujo MG, Branco NL. Kinesigenic paroxysmal hemidyskinesia as the initial presentation of multiple sclerosis. MedGenMed 2006;8:3.
9. Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord 2002;17:726-734. (Pubitemid 41295012)
10. Fischbeck KH, Layzer RB. Paroxysmal choreoathetosis associated with thyrotoxicosis. Ann Neurol 1979;6:453-454. (Pubitemid 10203435)
11. Uterga JM, Portillo MF, Iriondo I, et al. Symptomatic paroxysmal dystonia (non-kinesigenic forms): two new cases. Neurologia 1999;14:190-192. (Pubitemid 29268681)
12. Gay CT, Ryan SG. Paroxysmal kinesigenic dystonia after methylphenidate administration. J Child Neurol 1994;9:45-46. (Pubitemid 24022139)
13. Adam AM, Orinda DO. Focal paroxysmal kinesigenic choreoathetosis preceding the development of Steele-Richardson-Olszewski syndrome. J Neurol Neurosurg Psychiatry 1986;49:957-959.
14. Alemdar M, Selek A, Izeri P, et al. Fahraposs disease presenting with paroxysmal non-kinesigenic dyskinesia: a case report. Parkinsonism Relat Disord 2008;14(1):69-71.
15. Previdi P, Buzzi P. Paroxysmal dystonia due to a lesion of the cervical cord: case report. Ital J Neurol Sci 1992;13:521-523.
16. Houser MK, Soland VL, Bhatia KP, et al. Paroxysmal kinesigenic choreoathetosis: a report of 26 patients. J. Neurol 1999;246(2):120-126. (Pubitemid 29184964)
17. Gökay A, Gökay F. Oxcarbazepine therapy in paroxysmal kinesigenic choreoathetosis. Acta Neurol Scand 2000;101:344-345.
18. Pereira AC, Loo WJ, Bamford M, et al. Use of lamotrigine to treat paroxysmal kinesigenic choreoathetosis. J Neurol Neurosurg Psychiatry 2000;68:796-797. (Pubitemid 30265292)
19. Chillag KL, Deroos ST. Oxcarbazepine use in paroxysmal kinesigenic dyskinesia: report on four patients. Pediatr Neurol 2009;40:295-297.
20. Das SK, Ray K. Wilsonaposs disease: an update. Nat Clin Pract Neurol 2006;2:482-493.
21. Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007;86:112-121. (Pubitemid 46668060)
22. Smith CK, Mattson RH. Seizures in Wilsonaposs disease. Neurology 1967;17(11):1121-1123.
23. Starosta-Rubinstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilsonaposs disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987;44:365-370. (Pubitemid 17044083)
24. Vidailhet M. Paroxysmal dyskinesias as a paradigm of paroxysmal movement disorders. Curr Opin Neurol 2000;13:457-462.
25. Guerrini R. Idiopathic epilepsy and paroxysmal dyskinesia. Epilepsia 2001;42:36-41. (Pubitemid 32781379)
26. Singh R, Macdonell RA, Scheffer IE, et al. Epilepsy and paroxysmal movement disorders in families: evidence for shared mechanisms. Epileptic Disord 1999;1(2):93-99.
27. Huang CW, Cheng YC, Tsai JJ. Paroxysmal dyskinesia with secondary generalization of tonic-clonic seizures in pseudohypoparathyroidism. Epilepsia 2005;46(1):164-165.
28. Guerrini R, Sanchez-Carpintero R, Deonna T, et al. Early-onset absence epilepsy and paroxysmal dyskinesia. Epilepsia 2002;43(10):1224-1229. (Pubitemid 35176131)
29. Scheinberg IH, Sternlieb I. Wilsonaposs Disease. Philadelphia, PA: WB Saunders; 1984.
30. Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilsonaposs disease with initial penicillamine therapy. Arch Neurol 1987;44:490-493. (Pubitemid 17061929)
31. Glass JD, Reich SG, DeLong MR. Wilsonaposs disease. Development of neurological disease after beginning penicillamine therapy. Arch Neurol 1990;47(5):595-596. (Pubitemid 20155851)
32. Lucato LT, Otaduy MC, Barbosa ER, et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. AJNR Am J Neuroradiol 2005;26(5):1066-1071. (Pubitemid 43821950)